Chemomab Therapeutics Ltd.

Greetings, and welcome to ChemoMap third quarter 2022 earnings conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Barbara Lindham.

vice president of strategic communication thank you you may begin welcome to the chemo map therapeutics 2022 third quarter conference call thank you for attending i am barbara lindheim consulting vice president of strategic communications at chemo map with me today are dale post our chairman and ceo don marvin cfo chief operating officer and executive vice president dr adil moore our co-founder and chief scientific officer, and Dr. David Wiener, interim CMO. Before turning the call over to Dale, please take note of our forward-looking statement. Today's call may contain forward-looking statements, which may be identified by words such as may, could, will, expect, intend, plan, and other similar words and expressions. All forward-looking statements made today are based on management's current expectations, assumptions, and beliefs about our business and the environment in which we operate. These statements are subject to risks and uncertainties that could cause our actual results to materially differ from those expressed or implied on today's call. Listeners should not place undue reliance on forward-looking statements and are encouraged to review our earnings press release that we issued this morning together with our SEC filings for a more complete discussion of factors that could cause our actual results to differ materially from those expressed or implied in forward-looking statements. You can read a comprehensive list of those factors under the heading Risk Factors contained in our annual report on Form 10-K together with factors under similar headings and the other reports and materials we file with the SEC. Except as required by federal securities laws, HEMA-MAV does not undertake to publicly update or revise any forward-looking statements subsequent to the date made as a result of new information, future events, changing circumstances, or for any other reason. Let me now turn the call over to Dale.

Welcome to the ChemiMed conference call covering the third quarter of 2022. I am pleased to report that we have continued to make good progress on multiple fronts since our last call. Today, I will cover the following three advances we achieved during the third quarter. First, we advanced our clinical programs for CM-101, our first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target at the confluence of fibrosis and inflammation. We unveiled promising clinical data from an investigator-initiated lung injury study showing that CM-101 reduced biomarkers of lung inflammation and fibrogenesis in hospitalized COVID patients with severe pneumonia. Third, we presented new preclinical data at two major scientific meetings, one supporting the role of CCL24 in the pathophysiology of primary sclerosing cholangitis, and second, showing how Quimimab has used biomarkers as a strategic tool to inform and de-risk our drug development programs. We continue to make good progress in our CM101 clinical programs, as Dr. David Wiener will discuss in greater detail. In summary, we have been working to ensure that our Phase II liver fibrosis biomarker data will be analyzed and reported in the coming weeks. We continue to open new clinical sites for our Phase II trial in primary sclerosing cholangitis, or PSE, while expanding our patient recruitment and outreach efforts and submitting the global regulatory filings required to support trial expansion. Lastly, we have designed our planned Phase II trial in systemic sclerosis, or SSE, and initiated study startup activities. In support of our ongoing efforts to educate the scientific and medical communities about the critical role of CCL24 in fibroinflammatory diseases, the company made a number of presentations at important scientific meetings. Most significantly was Dr. Adi Moore's presentation of data from an investigator-initiated clinical study of CM101 in hospitalized COVID-19 patients with serious lung involvement. Adi will discuss these findings shortly. We were very pleased to see that CM-101 was well tolerated and demonstrated activity on key biomarkers of inflammation and fibrogenesis that are also relevant for systemic sclerosis. These CM-101-induced changes in biomarkers that have relevance across other fibrotic and inflammatory indications are a good example of the types of data we hope to see in the liver fibrosis biomarker study we will be reporting on later this year. At the important American Association for the Study of Liver Diseases, AASLD meeting, we presented a poster with data that reinforces the key role of CCL24 in the pathophysiology of PSC. Cumumab researchers used two animal models testing immune cell trafficking to show that CCL24 plays a critical role in the recruitment and migration of monocytes and neutrophils major players in causing the biliary damage that characterizes PSC. We also show that CM-101 can interfere with CCL24 stimulated migration of immune cells in an experiment animal model of PSC. This new study adds to the growing body of evidence validating our CCL24 target and confirming the therapeutic potential for our CCL24 neutralizing antibody. And yesterday, Dr. Moore was a featured speaker at the Anti-Fibrotic Drug Development Summit in Boston, where she gave a presentation highlighting the growing use of inflammatory and fibrotic biomarkers to inform clinical trial design and de-risk drug development. Adi showed how Quimimab has strategically used biomarkers throughout the drug discovery and development process as a key translational tool and how we are continuing to use them today. Let me now turn the call over to Adi Moore our co-founder, NCSL.